



## **Indraprastha Medical Corporation Limited**

(Indraprastha Apollo Hospitals)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi – 110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phone: 91-11-26925858, 26925801, Fax: 91-11-26823629

E-mail: [imclshares@apollohospitals.com](mailto:imclshares@apollohospitals.com), Website : <https://www.apollohospitals.com/delhi/>



**Ref: IMCL/CS/Newspaper/2026**

**4<sup>th</sup> February, 2026**

**The Manager  
Listing Department  
BSE Limited Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai, Maharashtra - 400001  
Scrip Code: 532150**

**The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra East,  
Mumbai, Maharashtra – 400051  
Symbol: INDRAMEDCO**

### **Sub.: Newspaper advertisement – Financial Results**

Dear Sir,

Pursuant to Regulation 30 read with Schedule III (Part A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit copies of the public notice of the financial results, published on 4th February, 2026, in the “Financial Express”, all India editions, in English language and in “Jansatta”, Delhi edition, in Hindi language.

You are requested to take the above information on record.

Thanking You,

Yours sincerely,

For Indraprastha Medical Corporation Limited

**Priya Ranjan  
AVP – Corporate Affairs & Legal  
(Company Secretary & Compliance Officer)**

**Encl.: As above**



## Saregama India Limited

CIN: L22213WB1946PLC014346

Regd. Office: 33, Jessore Road, Dum Dum, Kolkata - 700028.

Tel: 033-2551 2984/4773, E-mail: cs.sec@saregama.com, Web: www.saregama.com



### UNAUDITED FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

The Board of Directors of the Saregama India Limited ("Company"), at the Meeting held on Tuesday, 3rd February, 2026 approved the Unaudited Financial Results (Standalone and Consolidated) of the Company, for the quarter and nine months ended 31st December, 2025 ("Financial Results").

The aforementioned financial results along with the Limited Review Report thereon is available on the website of the stock exchanges ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)) and on the Company's website at <https://www.saregama.com/static/investors> and can be accessed by scanning the QR code.



On behalf of the Board

Sd/-  
Vikram Mehra  
Managing Director  
DIN: 03556680

Place: Kolkata  
Date : 3 February, 2026

Note: The above intimation is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.



## INDRAPRASTHA MEDICAL CORPORATION LIMITED

Registered office: Sarita Vihar, Delhi Mathura Road, New Delhi - 110076

Corporate Identity Number: L24232DL18881C039959

Phone: 91-11-26825858, 26925801, Fax: 91-11-26823229

E-mail: [indmshares@apollihospitals.com](mailto:indmshares@apollihospitals.com), Website: <https://www.apollihospitals.com/delhi>

### Extract of Statement of Unaudited Financial Results for the Quarter and Nine-months ended 31st December, 2025

S. No.	Particulars	Quarter ended		Period ended		Amount (Rs. in crore)	
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
1	Total income from operations (Net)	378.76	388.40	330.06	1139.12	1038.91	1379.01
2	Net Profit / (Loss) for the period (before Tax, Exceptional and Extraordinary items)	56.39	66.31	44.53	191.01	161.05	216.32
3	Net Profit / (Loss) for the period before tax (after Exceptional and Extraordinary items)	56.39	66.31	44.53	191.01	161.05	216.32
4	Net Profit / (Loss) for the period after tax (after Exceptional and Extraordinary items)	41.00	49.46	32.81	141.92	119.98	160.99
5	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after Tax))	41.45	46.99	32.70	144.38	120.65	160.17
6	Paid-up Equity share capital (Face value Rs. 10/- each)	91.67	91.67	91.67	91.67	91.67	91.67
7	Reserves (excluding Revaluation Reserves) as shown in the audited balance sheet of previous year	91.67	91.67	91.67	91.67	91.67	91.67
8	Earnings per share (of Rs. 10/- each) (for continuing and discontinued operations) - Basic & Diluted	4.47	5.40	3.58	15.48	13.09	17.56

The above is an extract of the detailed format of unaudited financial results for the quarter and nine-months ended 31st December, 2025, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results for the quarter and nine-months ended 31st December, 2025, are available on the Stock Exchange websites ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)) and on the company's website.



Shivakumar Pattabrahman  
(Managing Director)  
DIN: 08570283

Place : Chennai  
Date : 3<sup>rd</sup> February, 2026

Continued from previous page.

#### 4) Net Asset Value per Equity Share

On the basis of Financials:

Particulars	Net Asset Value (NAV) in Rs.
September 30, 2025	29.71
NAV as on March 31, 2025	24.67
NAV as on March 31, 2024	97.32
NAV as on March 31, 2023	48.71
NAV after the Offer: at Cap Price	53.28
NAV after the Offer: at Floor Price	51.66
NAV after the Offer: at Issue Price	51.66

\*Based on Restated Consolidated Financial Statements Note: Net Asset Value has been calculated as per the following formula:

Note: Net Asset Value has been calculated as per the following formula:

NAV = Net worth excluding preference share capital and revaluation reserve/Outstanding number of Equity shares outstanding during the year or period.

#### 5) Comparison with industry peers

S. No.	Name of the company	Face Value (Per Share)	CMP	EPS	P/E Ratio**	PAT (Amount in Lakhs)
1	Marushika Technology Limited	10.00	-	5.04	-	313.83
Peer Group*						
2	Vertexplus Technologies Limited	10.00	91.00	(3.70)	(24.59)	(202.00)
3	Synoptics Technologies Limited	10.00	50.00	4.01	12.47	340.45

Note: Industry Peer may be modified for finalization of Issue Price before filing Prospectus with ROC.

\* Sourced from Annual Reports, Unaudited Financials, NSE.

Notes:

- Considering the nature and turnover of business of the Company, the peers are not strictly comparable. However, the same have been included for broader comparison.
- The figures for Marushika Technology Limited are based on the restated Consolidated results for the year ended September 30, 2025.
- The figures for the peer group are based on Consolidated unaudited results for the period ended September 30, 2025.
- Current Market Price (CMP) is the closing price of respective scrip as on January 30, 2026.

For further details, see section titled Risk Factors beginning on page 32 and the Financials of the Company including profitability and return ratios, as set out in the section titled Auditors Report and Financial Information of Our Company beginning on page 280 of this Red Herring Prospectus for a more informed view.

#### Key financial and operational performance indicators ("KPIs")

Our company considers that KPIs included herein below have a bearing for arriving at the basis for Offer Price. The KPIs disclosed below have been approved by a resolution of our Audit Committee date January 22, 2026. Page 117 of 404 Further, the KPIs herein have been certified by M/s. GBSS & Associates, Chartered Accountants, by their certificate dated January 22, 2026 vide UDIN 26506712VA0HCE2433. Additionally, the Audit Committee on its meeting dated January 22, 2026 have confirmed that other than verified and audited KPIs set out below, our company has not disclosed to earlier investors at any point of time during the three years period prior to the date of the Red Herring Prospectus. For further details of our key performance indicators, see "Risk Factors", "Our Business", "Management's Discussion and Analysis of Financial Condition and Results of Operations" on pages 32, 160 and 262 respectively. We have described and defined them, where applicable, in "Definitions and Abbreviations" section on page no. 2. Our Company confirms that it shall continue to disclose the KPIs included in this section "Basis for Offer Price", on a periodic basis, at least once in a year (or for any lesser period as determined by the Board of directors, for a duration that is at least the later of (i) one year after the listing date or period specified by SEBI; or (ii) till the utilization of the Net Proceeds. Any change in these KPIs, during the period, will be explained by our Company as required under the SEBI ICDR Regulations.

Key metrics like revenue growth, EBITDA Margin, PAT Margin and low balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company.

#### Restated financial KPI indicators

Particulars	For period ended September 30, 2025	Financial Year ended March 31st, 2025	Financial Year ended March 31st, 2024	Financial Year ended March 31st, 2023
Revenue from operations <sup>(1)</sup>	4,863.94	8,524.87	6,066.23	3,699.90
Growth in Revenue from Operations <sup>(2)</sup>	40.55%	40.55%	64.90%	64.90%
EBITDA <sup>(3)</sup>	563.53	1,047.25	666.89	165.80
EBITDA (%) Margin <sup>(4)</sup>	11.59%	12.28%	9.34%	4.48%
EBITDA Growth Period on Period <sup>(5)</sup>	-	84.74%	241.90%	-
ROCE (%) <sup>(6)</sup>	13.89%	26.88%	18.63%	9.92%
Current Ratio <sup>(7)</sup>	1.33	1.33	1.20	1.13
Operating Cash Flow <sup>(8)</sup>	483.20	100.04	(637.77)	(295.33)
PAT <sup>(9)</sup>	313.83	620.64	314.11	40.25
ROE/ RoNW <sup>(10)</sup>	18.52%	52.77%	25.63%	11.16%
EPS <sup>(11)</sup>	5.04	10.21	5.50	0.74

Notes:

- Revenue from operations is the revenue generated by our Company.
- Growth in Revenue in percentage, Year on Year
- EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income
- EBITDA Margin is calculated as EBITDA divided by Revenue from Operations
- EBITDA Growth Rate Year on Year in Percentage
- ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus long-term debt.
- Current Ratio: Current Asset over Current Liabilities
- Operating Cash Flow: Net cash inflow from operating activities.
- PAT is mentioned as PAT for the period
- ROE/RoNW is calculated as PAT divided by average shareholders' equity.
- EPS is mentioned as EPS for the period.

1. Weighted Average Return on Net worth on restated consolidated financial statements for Financial Year ending 2025, 2024 and 2023 is 36.79%.

2. Disclosures as per clause (9)(K)(i) of Part A to Schedule VI, as applicable.

#### a) The price per share of our Company based on the primary issue of shares.

The details of the Equity Shares excluding shares issued under ESOP/ESOS and issuance of bonus shares during the 18 months preceding the date of this Red Herring Prospectus where such issuance is equal to or more than 5 per cent of the fully diluted paid-up share capital of the Issuer Company (calculated based on the pre-issue capital before such transaction), in a single transaction or multiple transactions combined together over a span of rolling 30 days; and

S. No.	Date of Allotment	No. of Equity Shares allotted	Face value (Rs.)	Issue Price (Rs.)	Issue Price Adjusted after Bonus Issue	Nature of consideration	Nature of Allotment
1	September 23, 2024	1,53,846	10	65	65	Cash	Right Issue

#### b) The price per share of our Company based on the secondary sale/acquisition of shares.

There have been no secondary sale / acquisitions of Equity Shares, where the promoters, members of the promoter group or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of this certificate, where either acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction/s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

BOOK RUNNING LEAD MANAGER		REGISTRAR TO THE ISSUE
	<b>NEXGEN FINANCIAL SOLUTIONS PRIVATE LIMITED</b>	<b>SKYLINE FINANCIAL SERVICES PRIVATE LIMITED</b>
	<b>Address:</b> 709, Madhuban Building, 55, Nehru Place, New Delhi-110019	<b>Address:</b> D-153 A, 1st Floor, Okhla Industrial Area, Phase - I, New Delhi-110020
	<b>Telephone:</b> +91 1141407600	<b>Telephone:</b> +91-11-40450193-97, Fax No: +91-11-26812683
	<b>Email:</b> <a href="mailto:ipo@nexgenfin.com">ipo@nexgenfin.com</a>	<b>Email:</b> <a href="mailto:ipo@skylinetm.com">ipo@skylinetm.com</a>
	<b>Website:</b> <a href="http://www.nexgenfin.com">www.nexgenfin.com</a>	<b>Website:</b> <a href="http://www.skylinetm.com">www.skylinetm.com</a>
	<b>Contact Person:</b> Ms. Ima Arora	<b>Contact Person:</b> Mr. Anuj Rana
	<b>SEBI Registration Number:</b> INM000011682	<b>SEBI Registration Number:</b> INR000003241
	<b>CIN:</b> U47899DL2000PT006340	<b>CIN:</b> U67100DL2010PT0208725
<b>AVAILABILITY OF RED HERRING PROSPECTUS:</b> Investors are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of the SEBI at <a href="http://www.sebi.gov.in">www.sebi.gov.in</a> , the website of the Lead Managers to the Issue at <a href="http://www.nexgenfin.com">www.nexgenfin.com</a> , website of company at <a href="http://www.marushika.in">www.marushika.in</a> and website of stock exchange at <a href="https://www.bseindia.com">https://www.bseindia.com</a> .		
<b>AVAILABILITY OF ABRIDGED PROSPECTUS:</b> A copy of the Abridged Prospectus shall be available on the website of the Company, BRLM and NSE EMERGE at <a href="http://www.nexgenfin.com">www.nexgenfin.com</a> , and <a href="https://www.nseindia.com/">https://www.nseindia.com/</a> .		
<b>SYNDICATE MEMBER- N.A.</b> <b>SUB-SYNDICATE MEMBER- N.A.</b>		
<b>AVAILABILITY OF BID-CUM-APPLICATION FORMS:</b> Bid-Cum-Application forms can be obtained from the Registered Office of the Company: Marushika Technology Limited (Telephone: 0120-4290383), Lead Managers: NEXGEN Financial Solutions Private Limited (Telephone: +91 1141407600), Bid-cum-application Forms will also be available on <a href="http://www.nexgenfin.com">www.nexgenfin.com</a> .		
<b>Place: Delhi</b> <b>Date: February 03, 2026</b>		

MARUSHIKA TECHNOLOGY LIMITED is proposing to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the Red Herring Prospectus with Registrar of Companies, Delhi on February 03, 2026, website of lead managers to the issue at [www.nexgenfin.com](http://www.nexgenfin.com), website of company at [www.marushika.in](http://www.marushika.in) and website of NSE Emerge i.e. <https://www.nseindia.com/>, respectively. Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled "Risk Factors" beginning on page 32 of the Red Herring Prospectus. Potential investors should not rely on the Red Herring Prospectus for making any investment decision. The Equity Shares offered in the Issue have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable U.S. state securities laws. There will be no public offering in the United States and the securities listed in this announcement are not being offered or sold in the United States.



**MAGNUS STEEL & INFRA LIMITED**  
(FORMERLY KNOWN AS MAGNUS RETAIL LIMITED)  
CIN NO: 124319MH1978PLC1416753  
Regd. Off: Unit No. 365, At/Post: Shirgaon, Tal: Niphad, Dist: Nashik - 422001  
Website: [www.magnussteelinfra.in](http://www.magnussteelinfra.in) ; Email: [magnussteelinfra@gmail.com](mailto:magnussteelinfra@gmail.com)  
Contact No.: +91 9112271471

**CORRIGENDUM TO THE NOTICE OF EXTRA-ORDINARY GENERAL MEETING**

Pursuant to Section 134 of the Companies Act, 2013 ("The Act") and Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Magnus Steel and Infra Limited had sent to the Members, the notice of extra-ordinary general meeting to be held on Tuesday, February 10, 2026.

Subsequent to the issuance of the said EGM Notice, the Company hereby informs that due to an inadvertent error, the percentage of post-preferential shareholding of the proposed allottee Ms Arti Anjaria, as disclosed in the said Notice of EGM, was incorrectly stated. The percentage of post preferential shareholding of Ms Arti Anjaria is 10.33% instead of 11.11%.

All other terms, information, and contents of the Notice of EGM remain unchanged. This corrigendum should be read in conjunction with the original Notice of EGM.


This Corrigendum is being issued to inform the shareholders regarding the modifications/amendments made in EGM Notice.

Accordingly, the Corrigendum to EGM Notice has been sent electronically to those members whose email-ids are registered with the Company.

The Corrigendum to the EGM Notice is available at the website of the company [www.magnussteelinfra.in](http://www.magnussteelinfra.in) and at the website of BSE [www.bseindia.com](http://www.bseindia.com).

**For Magnus Steel & Infra Limited**  
Sd/-  
Kshipra Bansal  
Company Secretary

**Place : Nashik**  
**Date : 03<sup>rd</sup> February 2026.**



**Mankind**  
Serving Life

## MANKIND PHARMA LIMITED

**Registered Office:** 208, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; **Tel.:** +91 11 4747 6600

**Corporate Office:** 262, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; **Tel.:** +91 11 4684 6700

**Email:** investors@mankindpharma.com, **Website:** www.mankindpharma.com, **CIN:** L74899DL1991PLC044843

### EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

(₹ in Crores except as stated otherwise)

S. No.	Particulars	Consolidated					
		For the quarter ended			For the nine months ended		For the year ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
1	Revenue from operations	3,567.20	3,697.16	3,198.79	10,834.71	9,128.07	12,207.44
2	Profit for the period/year before exceptional items and tax	615.59	624.02	488.33	1,780.10	2,000.90	2,516.33
3	Profit for the period/year after exceptional items and tax	413.88	520.18	377.87	1,378.68	1,577.60	2,006.59
4	Total comprehensive income for the period/ year	419.83	543.09	395.45	1,406.78	1,592.10	2,002.83
5	Paid up equity share capital	41.28	41.28	41.26	41.28	41.26	41.26
6	Other equity excluding revaluation reserve	N.A.	N.A.	N.A.	N.A.	N.A.	14,291.13
7	Earnings per equity share of face value of ₹ 1 each						
	- Basic EPS (in ₹)	9.90	12.39	9.29	32.91	38.87	49.17
	- Diluted EPS (in ₹)	9.89	12.38	9.27	32.87	38.79	49.08
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	


The key standalone financial information is as under:

(₹ in Crores except as stated otherwise)

S. No.	Particulars	For the quarter ended			For the nine months ended		For the year ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
1	Revenue from operations	2,632.68	2,636.95	2,431.15	7,839.36	7,387.95	9,507.41
2	Profit for the period/year before exceptional items and tax	588.71	525.53	512.90	1,610.41	1,865.05	2,146.50
3	Profit for the period/year after exceptional items and tax	449.47	462.27	405.45	1,329.04	1,495.22	1,780.30
4	Total comprehensive income for the period/year	452.53	478.30	414.83	1,349.21	1,564.67	1,846.63
5	Net worth (₹ Crores)	15,734.34	15,271.95	14,083.86	15,734.34	14,083.86	14,384.33
6	Debt equity ratio (times)	0.40	0.48	0.73	0.40	0.73	0.51
7	Debt service coverage ratio (times)	0.22	1.53	2.34	0.46	0.39	0.51
8	Interest service coverage ratio (times)	4.24	4.00	3.18	4.04	8.51	5.39

#### Notes:

- The above is an extract of the detailed format of Unaudited Consolidated and Standalone Financial Results for the quarter and nine months ended December 31, 2025 filed with the Stock Exchanges under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the above Financial Results are available on the Stock Exchanges website: [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) and also on the Company's website: [www.mankindpharma.com](http://www.mankindpharma.com). Full Financial Results can also be accessed by scanning the QR code given hereunder.
- The Unaudited Consolidated and Standalone Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 03, 2026.
- The above unaudited Consolidated and Standalone Financial Information is for continuing operations. Refer full format of the Quarterly Financial Results for discontinued operations.



For and on behalf of  
**MANKIND PHARMA LIMITED**  
Sd/-  
Sheetal Arora



Chief Executive Officer & Whole Time Director  
DIN : 00704299

Place: New Delhi  
Date: February 03, 2026



**THE BUSINESS DAILY**  
**FOR DAILY BUSINESS**

**FINANCIAL EXPRESS**  
Wired for Growth

(This is only an advertisement for information purposes and is not a prospectus announcement and not for distribution outside India.)																			
<div>  <div>Where Quality Comes First</div> </div>										<div>  <div>(Scan this code to view Prospectus)</div> </div>									
KANISHK ALUMINIUM INDIA LIMITED																			
Corporate Identity Number (CIN): U27109RJ2018PLC063198																			
<p>Our Company was originally incorporated as Company Limited by Shares under the name "Kanishk Aluminium Extrusions Private Limited" under the provisions of the Companies Act, 2013 and the Certificate of Incorporation was issued by Central Registration Centre, Manesar on December 05, 2018, vide certificate of incorporation bearing CIN U27109RJ2018PTC063198. Further, pursuant to Special Resolution passed by the shareholders at the Extra-Ordinary General Meeting held on August 26, 2022, the name of our Company was changed from "Kanishk Aluminium Extrusions Private Limited" to "Kanishk Aluminium India Private Limited" and a fresh certificate of incorporation consequent upon change of name was issued by the Registrar of Companies, Jaipur vide dated September 21, 2022. Subsequently, our Company was converted into a Public Limited Company and consequently the name of our Company was changed from "Kanishk Aluminium India Private Limited" to "Kanishk Aluminium India Limited" vide a fresh certificate of incorporation consequent upon conversion from private company to public company dated October 30, 2024, issued by the Registrar of Companies, Central Processing Centre, Our Company's Corporate Identity Number is CIN U27109RJ2018PLC063198. please refer to chapter titled "<b>History and Certain Other Corporate Matters</b>" beginning on Page No. 167 of the Prospectus.</p>																			
<p><b>Registered Office:</b> Plot No. E-849 A, Fourth Phase RICO, Boranada - 342001, Jodhpur, Rajasthan India.</p> <p><b>Website:</b> <a href="https://kanishkindia.co.in/">https://kanishkindia.co.in/</a>   <b>E-Mail:</b> <a href="mailto:cs@kanishkindia.co.in">cs@kanishkindia.co.in</a>   <b>Telephone No.:</b> +91 92570 61994</p> <p><b>Contact Person:</b> Ms. Prachi Mittal, Company Secretary and Compliance Officer</p>																			
OUR PROMOTERS: MR. PARMANAND AGARWAL, MR. ASHISH AGARWAL AND MRS. KHUSHBOO AGARWAL																			
BASIS OF ALLOTMENT																			
<p>INITIAL PUBLIC OFFERING OF 40,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH ("EQUITY SHARES") OF KANISHK ALUMINIUM INDIA LIMITED ("KANISHK" OR "OUR COMPANY" OR "THE ISSUER") FOR CASH AT A PRICE OF ₹73/- PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹ 63/- PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING TO ₹ 2,92,00,00,000 LAKHS COMPRISING OF FRESH ISSUE OF 40,00,000 EQUITY SHARES ("THE ISSUE") OF WHICH UP TO 2,00,00,000 EQUITY SHARES AGGREGATING TO ₹ 1,46,00,00,000 LAKHS RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 38,00,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH AT THE ISSUE PRICE OF ₹ 73 PER EQUITY SHARE AGGREGATING TO ₹ 2,77,40,00,000 LAKHS ("NET ISSUE"). THE ISSUE AND THE NET ISSUE CONSTITUTE 29.76% AND 28.27% OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, PLEASE REFER TO CHAPTER TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE 283 OF HTE PROSPECTUS.</p>																			
<p>THE FACE VALUE OF THE EQUITY SHARES IS ₹10 EACH AND THE ISSUE PRICE IS 7.3 TIMES OF THE FACE VALUE.</p>																			
<p><b>FIXED PRICE ISSUE AT ₹ 73.00 PER EQUITY SHARE</b> MINIMUM APPLICATION SIZE OF 3,200 EQUITY SHARES AND IN MULTIPLES OF 1,600 EQUITY SHARES THEREAFTER</p>																			
<p><b>OFFER PROGRAMME</b>      <b>OFFER OPENED ON: WEDNESDAY, JANUARY 28, 2026</b> <b>OFFER CLOSED ON: FRIDAY, JANUARY 30, 2026</b></p>																			
PROPOSED LISTING: WEDNESDAY, FEBRUARY 04, 2026																			
<p>The Equity Shares are proposed to be listed on the SME platform of BSE Limited i.e. BSE SME, in terms of the Chapter IX of the Securities and Exchange Board of India (Issue Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations"). Our Company has received an in-principle approval from BSE Limited ("BSE") for listing the Shares pursuant to letter dated September 08, 2025. The investors are advised to refer to page no. 278 of the Prospectus for the full text of the "Disclaimer Clause of the SME Platform of BSE Limited". The Designated Stock Exchange is BSE for this Issue. The trading or date of listing is proposed to be commenced on Wednesday, February 04, 2026 (subject to receipt of listing and trading approvals from the BSE).</p> <p>The Issue is being made through the Fixed Price process and the allocation in the Net Issue to the Individuals Investors category is made pursuant to Regulation 253(2) of the SEBI ICDR Regulations, wherein a minimum of 50% of the Net Issue to the Public is initially made available for allotment to Individual Investors. The balance of Net Issue to the Public is made available for allotment to Individual Applicants other than Individual Investors and other Investors including Corporate Bodies / Institutions irrespective of number of Shares applied for.</p> <p>All potential investors participated in the Issue only through an Application Supported by Blocked Amount ("ASBA") process including through UPI mode (as applicable) by providing details of the irrespective bank accounts and / or UPI IDs, in case of Retail Individual Investors, if applicable, by the Self Certified Syndicate Banks ("SCSBs").</p>																			
SUBSCRIPTION DETAILS																			
Detail of the Applications Received																			
Category of Investor		Gross Applications				After Technical Rejections				Valid Applications									
		No. of Applications	No. of Equity Shares			No. of Applications	No. of Equity Shares			No. of Applications									